PuSH - Publication Server of Helmholtz Zentrum München: Mutation-specific CAR T cells as precision therapy for IGLV3-21<sup>R110</sup> expressing high-risk chronic lymphocytic leukemia.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Märkl, F.* ; Schultheiß, C.* ; Ali, M.* ; Chen, S.S.* ; Zintchenko, M.* ; Egli, L.* ; Mietz, J.* ; Chijioke, O.* ; Paschold, L.* ; Spajic, S.* ; Holtermann, A.* ; Dörr, J.* ; Stock, S.* ; Zingg, A.* ; Läubli, H.* ; Piseddu, I.* ; Anz, D.* ; Minden, M.D.* ; Zhang, T.* ; Nerreter, T.* ; Hudecek, M.* ; Minguet, S.* ; Chiorazzi, N.* ; Kobold, S. ; Binder, M.*

Mutation-specific CAR T cells as precision therapy for IGLV3-21^R110 expressing high-risk chronic lymphocytic leukemia.

Nat. Commun. 15:993 (2024)

DOI

PMC

Abstract
Metrics
Extra information

The concept of precision cell therapy targeting tumor-specific mutations is appealing but requires surface-exposed neoepitopes, which is a rarity in cancer. B cell receptors (BCR) of mature lymphoid malignancies are exceptional in that they harbor tumor-specific-stereotyped sequences in the form of point mutations that drive self-engagement of the BCR and autologous signaling. Here, we use a BCR light chain neoepitope defined by a characteristic point mutation (IGLV3-21^R110) for selective targeting of a poor-risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR) T cells. We develop murine and humanized CAR constructs expressed in T cells from healthy donors and CLL patients that eradicate IGLV3-21^R110 expressing cell lines and primary CLL cells, but neither cells expressing the non-pathogenic IGLV3-21^G110 light chain nor polyclonal healthy B cells. In vivo experiments confirm epitope-selective cytolysis in xenograft models in female mice using engrafted IGLV3-21^R110 expressing cell lines or primary CLL cells. We further demonstrate in two humanized mouse models lack of cytotoxicity towards human B cells. These data provide the basis for advanced approaches of resistance-preventive and biomarker-guided cellular targeting of functionally relevant lymphoma driver mutations sparing normal B cells.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Chimeric Antigen Receptors; Xenograft Models; Light-chains; Immunoglobulin; Cll; Immunotherapy; Remissions; Transgene; Vectors; Driven

ISSN (print) / ISBN 2041-1723

e-ISSN 2041-1723

Journal Nature Communications

Quellenangaben Volume: 15, Issue: 1, Article Number: 993

Publisher Nature Publishing Group

Publishing Place London

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Unit for Clinical Pharmacology (KKG-EKLiP)

Grants Fritz-Bender-Stiftung
SFB-TRR 338/1
Monika-Kutzner-Stiftung
Deutsche Jose Carreras Leukamie-Stiftung
Wilhelm-Sander-Stiftung
Else-Kroner-Fresenius-Stiftung (IOLIN)
German Cancer Aid (AvantCAR.de)
Marie-Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Melanoma Research Alliance Grants
International Doctoral Program iTarget: Immunotargeting of Cancer - Elite Network of Bavaria
Intramural Roux program funding
DFG
LMU Munich's Institutional Strategy LMUexcellent

Bruno und Helene Joster Foundation
European Research Council
Bavarian Research Foundation (BAYCELLATOR)
Bundesministerium fur Bildung und Forschung Projects Oncoattract, CONTRACT and Beyondantibody
FOR2799
Deutsche Forschungsgemeinschaft (DFG)

PuSH - Publication Server of Helmholtz Zentrum München

Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.

Mutation-specific CAR T cells as precision therapy for IGLV3-21^R110 expressing high-risk chronic lymphocytic leukemia.